Cresco Labs Q4 2022 Earnings Report

Cresco Labs EPS Results

• Actual EPS: -$0.03
• Consensus EPS: -$0.02
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Cresco Labs Revenue Results

• Actual Revenue: $199.58 million
• Expected Revenue: $204.47 million
• Beat/Miss: Missed by -$4.89 million
• YoY Revenue Growth: N/A

Cresco Labs Announcement Details

• Quarter: Q4 2022
• Date: 3/21/2023
• Time: Q4 2022 Earnings Release

Cresco Labs (OTCMKTS:CRLBF), together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.